At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Lykos Therapeutics (formerly MAPS PBC)

We are proud to announce the FDA acceptance and priority review of our new drug application (NDA) filing for our investigational therapy for post-traumatic stress disorder #PTSD in adults. 

Learn more about this exciting milestone below.  

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced that PLOS has published the first study comparing the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe PTSD. The study explored how changes in self-experience impacted PTSD scores in the Company’s Phase 3, randomized, double-blind placebo-controlled study (MAPP1), previously published in Nature Portfolio. 

Results showed that compared to therapy with placebo, MDMA-assisted therapy had a statistically significant greater improvement in all self-experience measures such as self-compassion and being in touch with oneself. 

MAPS PBC raised more than $100 million including conversion of previously issued convertible notes with the closing of our oversubscribed Series A financing. Learn more about this significant milestone:


Same commitment, new name! MAPS PBC is now Lykos Therapeutics. Selecting the name Lykos – wolf in Greek – was a purposeful decision made to represent bravery, courage, loyalty and intelligence, all things we embody at our company. 

MAPS PBC announced today that the American Medical Association CPT III codes for psychedelic-assisted therapy\ies, first announced in July 2023, are now in effect. These temporary codes are assigned to emerging technologies to facilitate reimbursement and support access to psychedelic therapies in the United States, if such therapies receive regulatory approval by the #FDA. 
 
The new CPT codes will provide healthcare providers with a means to seek coverage and reimbursement for delivering psychedelic-assisted therapy if approved by the FDA.


Woven Science is a company specializing in mental health solutions and treatment.

Woven Science

GH Research is a provider of therapeutics for the management of mental diseases.

GH Research

Small Pharma is a company focused on developing novel mental health treatments.

Small Pharma

Lykos Therapeutics is a healthcare company focused on revolutionizing mental health treatment.

Lykos Therapeutics

doc.ai is a company offering advanced AI-driven healthcare solutions, including mental health.

doc.ai

Lightship is a company providing innovative mental health technology and resources.

Lightship

Alphaeon is a company specializing in mental health and wellness solutions.

Alphaeon

Lykos PBC is a mental health technology company that specializes in creating solutions to improve access to mental health care. The company focuses on leveraging technology to connect individuals with mental health professionals and resources, aiming to make mental health care more accessible and effective.

Lykos PBC

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 12, 2024 6:47 PM	1c8dba25
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	ba1f5366
crunchbase profile	general
li profile	general	May 12, 2024 6:47 PM	5548448b
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 12, 2024 6:47 PM	e40167c2
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:LYKOSPBC

Lykos PBC